Abstract

This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries though out the world. The main focus is on the competition at the level of single chemical entities, distinguishing between original brands and generic products. All the products containing major molecules whose patent expiration date lies between 2013 to 2021 are included in our sample. This study shows that how challenging is the task of meeting the global competition at the expiration of patent rights and furthermore what losses the pharmaceutical companies can bear after wards. This empirical investigation shows that the dynamics of drug R&D and its ultimate effect on the prices, especially generics, varies a lot. This kind of phenomena drastically hurts the investment made by the pharmaceutical companies. DOI: 10.5901/mjss.2014.v5n27p1728

Highlights

  • Pharmaceutical industry is a major driving force for global research and development (R&D) progress

  • Large pharmaceutical companies are investing in R&D, to discover innovative and exclusive drugs for the treatment of incurable diseases

  • Disappointing research productivity is arguably the biggest single factor behind the declining valuations of the sector over the past decade. Due to these declining trends pharmaceutical industry is faced with the loss of exclusivity and patent expiration of more than 110 products in the key U.S market between 2012 and 2014, the industry has stepped up its drive to buy in promising experimental medicines from small biotech companies

Read more

Summary

Introduction

Pharmaceutical industry is a major driving force for global research and development (R&D) progress. Large pharmaceutical companies are investing in R&D, to discover innovative and exclusive drugs for the treatment of incurable diseases. Huge investments are made over a long period of time to discover new drugs. The companies which get their products patented enjoy exclusive rights for specific time period, during which no other company can launch this molecule. Keeping in mind the generic war competition, several pharmaceutical companies are establishing their own generic version products just before exhaustion of patent monopoly period. A few studies have used explicit models of consumer and firm behavior to simulate the welfare losses implied by patent protection in developing countries [e.g., Challu (1991), Fink (2000), Maskus and Konan (1994), Nogues (1993), Subramanian (1995), Watal (2000)]

Research Methodology and Results
Results
The Pharmaceutical Industry: A Key Asset
Generics
Patents and Generics
15 Reclast
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call